Peer-reviewed veterinary case report
Radioactive iodine treatment for thyroid cancer in dogs
By Jegatheeson, Selvi et al.·Published in Veterinary and Comparative Oncology·2021·Melbourne Veterinary School, Faculty of Veterinary and Agricultural Sciences The University of Melbourne Werribee Victoria Australia, Australia·View original on Crossref →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Response of canine thyroid carcinomas to radioiodine
- Species:
- dog
Plain-English summary
A group of 66 dogs with thyroid cancer received radioactive iodine (131I) treatment to see how well it worked. About 35% of the dogs showed a positive response, with some experiencing complete or partial shrinkage of their tumors. Most dogs also showed improvement in their symptoms, such as increased energy or appetite. On average, dogs lived for about 564 days after treatment, and those who had not received prior therapy had better outcomes. Overall, radioactive iodine can help manage thyroid cancer in dogs and improve their quality of life.
People also search for: dog thyroid cancer treatment · radioactive iodine for dogs · dog cancer survival rate
Abstract
AbstractRadioactive iodine (131I) has previously been reported to prolong survival in dogs with thyroid carcinoma. This study aimed to describe tumour response and progression‐free interval (PFI) in dogs with thyroid carcinomas treated with131I. Secondary aims were to describe overall survival time (OST) and prognostic factors. A bi‐institutional retrospective review of records identified 66 dogs with thyroid carcinoma treated with131I from January 2010 to April 2020. Response was described using RECIST or a subjective response assessment where specific tumour measurements were not available. Forty‐eight dogs (72.7%) were treatment naïve and 18 dogs (27.3%) had received prior therapy at the time of131I treatment. Objective responses were available for 34 dogs and subjective responses for 58 dogs. The overall response rate was 35.3% (four complete and eight partial responses). Improvement of clinical signs was seen in 76.2% of dogs (32/42). Kaplan–Meier‐estimated median PFI (95% confidence interval [CI]) was 301 (217–578) days and OST (95% CI) was 564 (421–865) days. Prior therapy was associated with a lower hazard for progression (hazard ratio [HR] 0.260 95% CI 0.123–0.548,p = .0004). Treatment of thyroid carcinoma using131I can effectively alleviate clinical signs and reduce disease burden in a proportion of dogs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Crossref: https://doi.org/10.1111/vco.12770